Prophylactic lidocaine: uncertain benefits in emergency settings. (Q51859439)

14 April 2018

title

Prophylactic lidocaine: uncertain benefits in emergency settings. (English)

1 reference

14 April 2018

0 references

Borak J

1

1 reference

14 April 2018

Veilleux S

series ordinal

2

1 reference

14 April 2018

language of work or name

English

0 references

publication date

1 September 1982

1 reference

14 April 2018

Annals of Emergency Medicine

published in

1 reference

14 April 2018

volume

11

1 reference

14 April 2018

issue

9

1 reference

14 April 2018

page(s)

493-496

1 reference

14 April 2018

Lidocaine prophylaxis against ventricular fibrillation in acute myocardial infarction

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2882%2980071-1

7 January 2021

Lidocaine prophylaxis in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2882%2980071-1

7 January 2021

Prophylactic lidocaine in suspected acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2882%2980071-1

7 January 2021

Clinical biostatistics. 3. The architecture of clinical research.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2882%2980071-1

7 January 2021

Clinical biostatistics. IV. The architecture of clinical research (continued).

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2882%2980071-1

7 January 2021

Clinical biostatistics. V. The architecture of clinical research (concluded).

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2882%2980071-1

7 January 2021

A Critique of Methodology in Studies of Anticoagulant Therapy for Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2882%2980071-1

7 January 2021

Clinical biostatistics. VII. The rancid sample, the tilted target, and the medical poll-bearer

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2882%2980071-1

7 January 2021

Acute phase of myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2882%2980071-1

7 January 2021

Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2882%2980071-1

7 January 2021

Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2882%2980071-1

7 January 2021

The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2882%2980071-1

7 January 2021

Electrophysiology and pharmacology of cardiac arrhythmias. V. Cardiac antiarrhythmic effects of lidocaine

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2882%2980071-1

7 January 2021

The origin of ventricular arrhythmias 24 hours following experimental anterior septal coronary artery occlusion

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2882%2980071-1

7 January 2021

Electrocardiographic antecedents of primary ventricular fibrillation. Value of the R-on-T phenomenon in myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2882%2980071-1

7 January 2021

Drug therapy: bretylium

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2882%2980071-1

7 January 2021

Should lidocaine be administered routinely to all patients after acute myocardial infarction?

1 reference

https://api.crossref.org/works/10.1016%2FS0196-0644%2882%2980071-1

7 January 2021

10.1016/S0196-0644(82)80071-1

Identifiers

DOI

1 reference

14 April 2018

1 reference

14 April 2018